Drug intelligence / Profile preview

NVD-M2

Development stage: Preclinical
Lead developer: Novadip Biosciences
Modality: Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intratumoral, Intraarticular, Implant

Overview

NVD-M2 is a preclinical cell therapy candidate developed by Novadip Biosciences for the treatment of solid tumors, including osteosarcoma, glioblastoma, and metastatic cancers. The therapy utilizes microRNA and proteins delivered via a matrisome scaffold to modulate tumor biology. The approach leverages Novadip’s 3M3 technology platform to generate highly specific miRNAs/exosomes that can inhibit cellular proliferation, modulate bone remodeling, and target tumor development. NVD-M2 is designed as a regenerative medicine product with potential applications in both oncology (solid tumors) and systemic tissue diseases such as osteoporosis and osteoarthritis[1][4][7].

Beyond the preview

Go deeper on NVD-M2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVD-M2.

Explore the full profile